Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?

Company Performance - Halozyme Therapeutics (HALO) shares have increased by 20.6% over the past month, reaching a new 52-week high of $74.44 [1] - The stock has gained 53.4% since the beginning of the year, outperforming the Zacks Medical sector, which saw a -2.1% gain, and the Zacks Medical - Biomedical and Genetics industry, which had a 3.6% return [1] Earnings and Revenue - Halozyme has consistently beaten earnings estimates, with the latest report on August 5, 2025, showing an EPS of $1.54 against a consensus estimate of $1.23, and revenue exceeding estimates by 13.84% [2] - For the current fiscal year, earnings are projected at $6.18 per share with revenues of $1.32 billion, reflecting a 46.1% increase in EPS and a 29.58% increase in revenues [3] - The next fiscal year is expected to see earnings of $7.56 per share and revenues of $1.59 billion, indicating year-over-year changes of 22.33% and 20.91%, respectively [3] Valuation Metrics - Halozyme's current valuation metrics show a trading multiple of 11.9X current fiscal year EPS estimates, below the peer industry average of 21.1X [7] - The stock trades at a trailing cash flow basis of 15.8X, matching its peer group's average, and has a PEG ratio of 0.38, suggesting it is not in the top tier from a value perspective [7] Zacks Rank and Style Scores - Halozyme holds a Zacks Rank of 1 (Strong Buy) due to favorable earnings estimate revisions from analysts [8] - The stock has a Value Score of B, a Growth Score of D, and a Momentum Score of A, resulting in a combined VGM Score of B [6][9] Industry Comparison - Kamada Ltd. (KMDA) is a notable peer with a Zacks Rank of 2 (Buy) and strong earnings performance, having beaten consensus estimates by 44.44% last quarter [10][11] - The Medical - Biomedical and Genetics industry is positioned in the top 40% of all industries, indicating positive market conditions for both HALO and KMDA [12]